<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>The Peptide Institute</title>
    <link>https://thepeptideinstitute.org/</link>
    <description>Latest news and articles from The Peptide Institute, an independent educational publication. Not medical advice.</description>
    <language>en-us</language>
    <atom:link href="https://thepeptideinstitute.org/rss.xml" rel="self" type="application/rss+xml" />
    <lastBuildDate>Mon, 02 Nov 2026 12:00:00 GMT</lastBuildDate>
    <item>
      <title>It happened. BPC-157 and TB-500 just got a legal pharmacy lane.</title>
      <link>https://thepeptideinstitute.org/news/hhs-peptide-compounding-policy-bpc-157-tb-500/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/news/hhs-peptide-compounding-policy-bpc-157-tb-500/</guid>
      <pubDate>Mon, 02 Nov 2026 12:00:00 GMT</pubDate>
      <description>HHS published its long-awaited peptide policy on October 30. Six peptides, including both halves of the Wolverine stack, can now be made by licensed pharmacies with a prescription. Here is what changed and what did not.</description>
    </item>
    <item>
      <title>Retatrutide went head to head with Ozempic. It was not close.</title>
      <link>https://thepeptideinstitute.org/news/retatrutide-vs-ozempic-transcend-t2d-2/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/news/retatrutide-vs-ozempic-transcend-t2d-2/</guid>
      <pubDate>Mon, 02 Nov 2026 12:00:00 GMT</pubDate>
      <description>In a new phase 3 trial, people on retatrutide lost more than twice as much weight as people on the top dose of Ozempic. Here is what Lilly reported.</description>
    </item>
    <item>
      <title>Retatrutide just took on sleep apnea. The results are hard to sleep on.</title>
      <link>https://thepeptideinstitute.org/news/retatrutide-sleep-apnea-nejm-2026/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/news/retatrutide-sleep-apnea-nejm-2026/</guid>
      <pubDate>Mon, 26 Oct 2026 12:00:00 GMT</pubDate>
      <description>Two new phase 3 trials in the New England Journal of Medicine found big drops in nightly breathing interruptions, plus serious weight loss. Here is what they showed.</description>
    </item>
    <item>
      <title>Retatrutide phase 3 results are in. Here is what the TRIUMPH trials actually showed.</title>
      <link>https://thepeptideinstitute.org/research/retatrutide-phase-3-triumph-results/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/research/retatrutide-phase-3-triumph-results/</guid>
      <pubDate>Mon, 19 Oct 2026 12:00:00 GMT</pubDate>
      <description>Five positive phase 3 trials, average weight loss near 28% in the biggest one, and two peer-reviewed papers. Here is the real scorecard, and what is still unknown.</description>
    </item>
    <item>
      <title>FDA advisers just backed BPC-157, TB-500 and KPV. This could change the healing game.</title>
      <link>https://thepeptideinstitute.org/news/fda-pcac-july-2026-peptide-vote/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/news/fda-pcac-july-2026-peptide-vote/</guid>
      <pubDate>Sat, 17 Oct 2026 12:00:00 GMT</pubDate>
      <description>The two halves of the Wolverine stack just won a big vote from an FDA advisory committee. Here is what happened, why it matters, and the White House review that could come next.</description>
    </item>
    <item>
      <title>What a Peptide Is (and Is Not)</title>
      <link>https://thepeptideinstitute.org/guides/what-a-peptide-is/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/guides/what-a-peptide-is/</guid>
      <pubDate>Fri, 02 Oct 2026 12:00:00 GMT</pubDate>
      <description>Midlife feeds treat “peptides” like a product aisle. Biology treats them as a molecule class. Here is the calm distinction, plus why mechanism is not the same as proof.</description>
    </item>
    <item>
      <title>How to Grade Peptide Claims Without a Statistics Degree</title>
      <link>https://thepeptideinstitute.org/guides/how-to-grade-peptide-claims/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/guides/how-to-grade-peptide-claims/</guid>
      <pubDate>Fri, 02 Oct 2026 12:00:00 GMT</pubDate>
      <description>A portable habit for social feeds: grade mechanism, benefit, safety, and purity claims separately, then place the whole pitch on an evidence ladder.</description>
    </item>
    <item>
      <title>A Certificate of Analysis Is Not a Hall Pass</title>
      <link>https://thepeptideinstitute.org/guides/coa-literacy/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/guides/coa-literacy/</guid>
      <pubDate>Fri, 02 Oct 2026 12:00:00 GMT</pubDate>
      <description>A COA is a lab report about a sample under stated methods, not a blessing for personal use. Here is how to read lot, method, date, and lab without turning a PDF into a shopping list.</description>
    </item>
    <item>
      <title>Repair Buzz and the Angiogenesis Tradeoff</title>
      <link>https://thepeptideinstitute.org/guides/repair-angiogenesis-tradeoff/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/guides/repair-angiogenesis-tradeoff/</guid>
      <pubDate>Fri, 02 Oct 2026 12:00:00 GMT</pubDate>
      <description>Healing often recruits new blood-vessel growth. Tumors can use related pathways. Here is the pattern literacy behind “repair peptide” talk, without turning BPC-style names into a protocol.</description>
    </item>
    <item>
      <title>Coach, Clinician, Vendor: Keep the Lanes Separate</title>
      <link>https://thepeptideinstitute.org/guides/coach-clinician-vendor-lanes/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/guides/coach-clinician-vendor-lanes/</guid>
      <pubDate>Fri, 02 Oct 2026 12:00:00 GMT</pubDate>
      <description>Three roles collapse into one voice on peptide feeds. Separating clinician care, coaching habits, and vendor fulfillment is a harm-reduction habit, not a personality test.</description>
    </item>
    <item>
      <title>Retatrutide and the replication problem</title>
      <link>https://thepeptideinstitute.org/research/retatrutide-and-the-replication-problem/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/research/retatrutide-and-the-replication-problem/</guid>
      <pubDate>Tue, 25 Aug 2026 12:00:00 GMT</pubDate>
      <description>Purity across our Retatrutide samples ranged from 58.2% to 99.7%. Here is the context.</description>
    </item>
    <item>
      <title>Survodutide: separating the mechanism from the marketing</title>
      <link>https://thepeptideinstitute.org/research/survodutide-separating-the-mechanism-from-the-marketing/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/research/survodutide-separating-the-mechanism-from-the-marketing/</guid>
      <pubDate>Mon, 24 Aug 2026 12:00:00 GMT</pubDate>
      <description>Purity across our Survodutide samples ranged from 98.2% to 99.4%. Here is the context.</description>
    </item>
    <item>
      <title>New Retatrutide data: reading the results critically</title>
      <link>https://thepeptideinstitute.org/research/new-retatrutide-data-reading-the-results-critically/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/research/new-retatrutide-data-reading-the-results-critically/</guid>
      <pubDate>Sun, 23 Aug 2026 12:00:00 GMT</pubDate>
      <description>Purity across our Retatrutide samples ranged from 58.2% to 99.7%. Here is the context.</description>
    </item>
    <item>
      <title>Sermorelin dose-response findings and what they leave open</title>
      <link>https://thepeptideinstitute.org/research/sermorelin-dose-response-findings-and-what-they-leave-open/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/research/sermorelin-dose-response-findings-and-what-they-leave-open/</guid>
      <pubDate>Sat, 22 Aug 2026 12:00:00 GMT</pubDate>
      <description>Purity across our Sermorelin samples ranged from 93.2% to 98.5%. Here is the context.</description>
    </item>
    <item>
      <title>CJC-1295 dose-response findings and what they leave open</title>
      <link>https://thepeptideinstitute.org/research/cjc-1295-dose-response-findings-and-what-they-leave-open/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/research/cjc-1295-dose-response-findings-and-what-they-leave-open/</guid>
      <pubDate>Sat, 22 Aug 2026 12:00:00 GMT</pubDate>
      <description>A close reading of the CJC-1295 evidence, without the marketing layer.</description>
    </item>
    <item>
      <title>Retesting Semaglutide: following up on last cycle&apos;s discrepancies</title>
      <link>https://thepeptideinstitute.org/investigations/retesting-semaglutide-following-up-on-last-cycles-discrepancies/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/investigations/retesting-semaglutide-following-up-on-last-cycles-discrepancies/</guid>
      <pubDate>Fri, 21 Aug 2026 12:00:00 GMT</pubDate>
      <description>Purity across our Semaglutide samples ranged from 58.1% to 99.1%. Here is the context.</description>
    </item>
    <item>
      <title>We Tested BPC-157 From 12 Companies. Here’s What We Found.</title>
      <link>https://thepeptideinstitute.org/investigations/bpc-157-multi-company-testing-investigation/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/investigations/bpc-157-multi-company-testing-investigation/</guid>
      <pubDate>Tue, 18 Aug 2026 12:00:00 GMT</pubDate>
      <description>23 samples, 12 sellers, one compound with almost no human evidence behind it. Measured purity ranged from 61% to 98.9%.</description>
    </item>
    <item>
      <title>Tirzepatide: separating the mechanism from the marketing</title>
      <link>https://thepeptideinstitute.org/research/tirzepatide-separating-the-mechanism-from-the-marketing/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/research/tirzepatide-separating-the-mechanism-from-the-marketing/</guid>
      <pubDate>Tue, 18 Aug 2026 12:00:00 GMT</pubDate>
      <description>A close reading of the Tirzepatide evidence, without the marketing layer.</description>
    </item>
    <item>
      <title>Pricing pressure reshapes the GHK-Cu category</title>
      <link>https://thepeptideinstitute.org/news/pricing-pressure-reshapes-the-ghk-cu-category/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/news/pricing-pressure-reshapes-the-ghk-cu-category/</guid>
      <pubDate>Tue, 18 Aug 2026 12:00:00 GMT</pubDate>
      <description>4 independently tested samples across 4 companies, and what the results say about GHK-Cu.</description>
    </item>
    <item>
      <title>Compounding rules tighten around Epitalon</title>
      <link>https://thepeptideinstitute.org/news/compounding-rules-tighten-around-epitalon/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/news/compounding-rules-tighten-around-epitalon/</guid>
      <pubDate>Sat, 15 Aug 2026 12:00:00 GMT</pubDate>
      <description>1 independently tested samples across 1 companies, and what the results say about Epitalon.</description>
    </item>
    <item>
      <title>The Peptide Index™: August 2026 rankings update</title>
      <link>https://thepeptideinstitute.org/news/rankings-update-august-2026/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/news/rankings-update-august-2026/</guid>
      <pubDate>Fri, 14 Aug 2026 12:00:00 GMT</pubDate>
      <description>Apex Peptides holds the top position; Cascade Research Group drops 17 points after failed verification; BioRegen enters the top five.</description>
    </item>
    <item>
      <title>Reading Ipamorelin research without a pharmacology degree</title>
      <link>https://thepeptideinstitute.org/guides/reading-ipamorelin-research-without-a-pharmacology-degree/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/guides/reading-ipamorelin-research-without-a-pharmacology-degree/</guid>
      <pubDate>Fri, 14 Aug 2026 12:00:00 GMT</pubDate>
      <description>7 independently tested samples across 5 companies, and what the results say about Ipamorelin.</description>
    </item>
    <item>
      <title>What the evidence actually supports for BPC-157</title>
      <link>https://thepeptideinstitute.org/research/what-the-evidence-actually-supports-for-bpc-157/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/research/what-the-evidence-actually-supports-for-bpc-157/</guid>
      <pubDate>Tue, 11 Aug 2026 12:00:00 GMT</pubDate>
      <description>23 independently tested samples across 12 companies, and what the results say about BPC-157.</description>
    </item>
    <item>
      <title>BPC-157 mechanisms: what the latest evidence actually supports</title>
      <link>https://thepeptideinstitute.org/research/bpc-157-mechanisms-evidence-review/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/research/bpc-157-mechanisms-evidence-review/</guid>
      <pubDate>Mon, 10 Aug 2026 12:00:00 GMT</pubDate>
      <description>Angiogenesis modulation, growth-factor signaling, and the gaps between rodent data and human claims.</description>
    </item>
    <item>
      <title>How strong is the safety data for Tesamorelin?</title>
      <link>https://thepeptideinstitute.org/research/how-strong-is-the-safety-data-for-tesamorelin/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/research/how-strong-is-the-safety-data-for-tesamorelin/</guid>
      <pubDate>Mon, 10 Aug 2026 12:00:00 GMT</pubDate>
      <description>1 independently tested samples across 1 companies, and what the results say about Tesamorelin.</description>
    </item>
    <item>
      <title>Peptide stability: how storage and handling impact purity</title>
      <link>https://thepeptideinstitute.org/guides/peptide-stability-storage-handling/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/guides/peptide-stability-storage-handling/</guid>
      <pubDate>Sun, 09 Aug 2026 12:00:00 GMT</pubDate>
      <description>Lyophilized peptides are more fragile than the marketing suggests. What degradation looks like in our testing data.</description>
    </item>
    <item>
      <title>New Cagrilintide data: reading the results critically</title>
      <link>https://thepeptideinstitute.org/research/new-cagrilintide-data-reading-the-results-critically/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/research/new-cagrilintide-data-reading-the-results-critically/</guid>
      <pubDate>Sat, 08 Aug 2026 12:00:00 GMT</pubDate>
      <description>7 independently tested samples across 4 companies, and what the results say about Cagrilintide.</description>
    </item>
    <item>
      <title>New study explores oral delivery of GLP-1 peptides</title>
      <link>https://thepeptideinstitute.org/news/oral-glp1-delivery-study/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/news/oral-glp1-delivery-study/</guid>
      <pubDate>Fri, 07 Aug 2026 12:00:00 GMT</pubDate>
      <description>Absorption enhancers push oral bioavailability past thresholds previously considered impractical for large peptides.</description>
    </item>
    <item>
      <title>Major lab raises concerns about peptide purity industry-wide</title>
      <link>https://thepeptideinstitute.org/news/lab-concerns-peptide-purity-industry/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/news/lab-concerns-peptide-purity-industry/</guid>
      <pubDate>Thu, 06 Aug 2026 12:00:00 GMT</pubDate>
      <description>An analytical laboratory serving the research-chemical sector reports rising failure rates across client samples.</description>
    </item>
    <item>
      <title>The State of the Peptide Industry 2026</title>
      <link>https://thepeptideinstitute.org/investigations/state-of-the-peptide-industry-2026/</link>
      <guid isPermaLink="true">https://thepeptideinstitute.org/investigations/state-of-the-peptide-industry-2026/</guid>
      <pubDate>Thu, 06 Aug 2026 12:00:00 GMT</pubDate>
      <description>224 independent tests across 19 companies and 55 compounds. The industry is bifurcating, and the gap is measurable.</description>
    </item>
  </channel>
</rss>
